Helio Genomics Partners With Syneos to Roll Out AI Liver Cancer Test

What Happened

Helio Genomics announced a commercial partnership with Syneos Health on Monday to accelerate nationwide adoption of HelioLiver, an AI-powered blood test designed to detect liver cancer at an early stage. The partnership gives Helio Genomics access to Syneos Health's established commercial infrastructure to scale distribution of the test across the United States.

What HelioLiver Does

HelioLiver is a blood-based diagnostic test that uses artificial intelligence to identify markers associated with hepatocellular carcinoma, the most common form of primary liver cancer, at an early stage. The test is designed to be administered through a standard blood draw, positioning it as an alternative or supplement to imaging-based screening methods currently used in clinical practice. Helio Genomics describes itself as an AI-powered TechBio company focused on early cancer detection.

The Partnership

Syneos Health is a contract research and commercial solutions organization that works with biopharmaceutical and medical technology companies to bring products to market. Under the terms announced Monday, Syneos Health will support the commercial rollout of HelioLiver across the United States. The companies did not disclose the financial terms of the agreement in the announcement.

The partnership is structured to address what Helio Genomics identifies as a significant gap in liver cancer screening. Liver cancer is frequently diagnosed at a late stage, when treatment options are more limited. Early detection has been associated with higher survival rates in clinical literature, though Helio Genomics did not provide specific clinical outcome data in Monday's announcement.

Market Context

Liver cancer represents a growing area of focus for AI-assisted diagnostics. The broader liquid biopsy and AI diagnostics market has attracted significant investment in recent years, with several companies developing blood-based tests for various cancer types. In April 2026, the U.S. Food and Drug Administration granted Breakthrough Device Designation to a separate AI-powered test developed by Valar Labs for bladder cancer detection, indicating regulatory interest in AI-assisted oncology diagnostics across multiple cancer types.

HelioLiver has not yet received FDA approval or clearance as of the time of this announcement. Helio Genomics did not specify the current regulatory status of the test or the timeline for any anticipated regulatory submissions in Monday's release.

What Was Said

Helio Genomics characterized the partnership with Syneos Health as a strategic step toward making HelioLiver accessible to healthcare providers and patients at scale. The company's announcement described Syneos Health as a partner capable of providing the commercial reach required to move the product beyond early market entry. Neither company released direct quotes from named executives in the wire report available at publication time.

Who the Companies Are

Helio Genomics is a privately held company based in the United States. Its product pipeline is focused on blood-based, AI-assisted cancer diagnostics. Syneos Health is a publicly traded company headquartered in Morrisville, North Carolina, that provides integrated biopharmaceutical solutions including clinical development and commercial services. Syneos Health works with clients across the pharmaceutical, biotechnology, and medical device sectors.

What Happens Next

Helio Genomics and Syneos Health are expected to begin executing on the commercial rollout of HelioLiver in the United States, with the scope and timeline of that process subject to any applicable regulatory requirements.